LIG4 and cancer: Many DNA-PKs inhibitors (such as IC86621 and NVP-BEZ236) showed dominant negative effects on both NHEJ and HR and are therefore excellent candidates for augmenting cancer radiotherapy.33,34 SCR7, another NHEJ inhibitor, could inhibit DNA ligase IV and improve efficacy of chemo- and radiotherapy.35